It is well established that chronic glucocorticoid exposure causes hyperglycemia. While glucocorticoid receptor (GR) stimulates hepatic gluconeogenic gene transcription, additional mechanisms are activated by chronic glucocorticoid exposure to enhance gluconeogenesis. We found that chronic glucocorticoid treatment activated sphingosine-1-phosphate (S1P)-mediated signaling. Hepatic knockdown of hepatic S1P receptor 1 (S1PR1) had no effect on chronic glucocorticoid-induced glucose intolerance but elevated fasting plasma insulin levels. In contrast, hepatic S1PR3 knockdown exacerbated chronic glucocorticoid-induced glucose intolerance without affecting fasting plasma insulin levels. Finally, hepatic S1PR2 knockdown attenuated chronic glucocorticoid-induced glucose intolerance and reduced fasting plasma insulin levels. Here, we focused on dissecting the role of S1PR2 signaling in chronic glucocorticoid response on glucose homeostasis. We found that chronic glucocorticoid-induced hepatic gluconeogenesis, gluconeogenic gene expression, and GR recruitment to the glucocorticoid response elements (GREs) of gluconeogenic genes were all reduced in hepatic S1PR2 knockdown male mice. Hepatic S1PR2 knockdown also enhanced glucocorticoid suppression of RAR-related orphan receptor γ (RORγ) expression. Hepatic RORγ overexpression in hepatic S1PR2 knockdown mice restored glucocorticoid-induced glucose intolerance, gluconeogenic gene expression, and GR recruitment to their GREs. Conversely, RORγ antagonist and the reduction of hepatic RORγ expression attenuated such glucocorticoid effects. Thus, chronic glucocorticoid exposure induces an S1PR2-RORγ axis to cooperate with GR to enhance hepatic gluconeogenesis. Overall, this work provides novel mechanisms of and pharmaceutical targets against steroid-induced hyperglycemia.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10588286PMC
http://dx.doi.org/10.2337/db22-0605DOI Listing

Publication Analysis

Top Keywords

chronic glucocorticoid
24
glucocorticoid exposure
16
chronic glucocorticoid-induced
16
glucocorticoid-induced glucose
16
glucose intolerance
16
hepatic s1pr2
16
s1pr2 knockdown
16
hepatic
13
hepatic gluconeogenesis
12
gluconeogenic gene
12

Similar Publications

Application of Nanomaterials Targeting Immune Cells in the Treatment of Chronic Inflammation.

Int J Nanomedicine

December 2024

Department of Oral Implantology, Hospital of Stomatology, Jilin University, Changchun, 130021, People's Republic of China.

Article Synopsis
  • Chronic inflammation is linked to various diseases and is characterized by prolonged immune cell activation, resulting in tissue damage.
  • Despite the effectiveness of current anti-inflammatory medications, they often have side effects due to non-specific targeting.
  • Nanoparticle drug delivery shows promise for targeted therapy in inflammation, but improvements are needed to specifically target different immune cell types for enhanced therapeutic effects.
View Article and Find Full Text PDF
Article Synopsis
  • The pathogenesis of long COVID (LC) involves uncertainty, complicating the search for effective therapies.
  • The hypothesis suggests that chronic damage to the body's anti-inflammatory mechanisms, particularly through the vagus nerve, HPA axis, and mitochondrial function, plays a crucial role in LC development.
  • The theory posits that SARS-CoV-2 alters these systems at various levels, leading to persistent inflammation due to impaired anti-inflammatory responses from acetylcholine and cortisol, warranting further investigation into glucocorticoid receptor sensitivity and potential long-term epigenetic effects.
View Article and Find Full Text PDF

Systemic lupus erythematosus (SLE) is a typical autoimmune disease; although severe disease and refractoriness to existing therapies are still experienced, the number of cases resistant to remission induction has decreased with the establishment of various therapies. However, improving long-term prognosis remains a challenge due to the unavoidable prolonged use of non-selective glucocorticoids. To investigate the additional effect of belimumab in the chronic phase, we included 28 of 46 patients with SLE who were initiated on belimumab between January 2018 and October 2022 for glucocorticoid reduction.

View Article and Find Full Text PDF

Objectives: Glucocorticoid cosecretion is more common in primary aldosteronism (PA) than previously thought. Chronic subtle cortisol excess in patients with mild autonomous cortisol secretion (MACS) negatively affects bone health. This study aimed to evaluate the impact of MACS on bone density and turnover markers in PA patients.

View Article and Find Full Text PDF

Purpose: Atopic dermatitis (AD) is the most common chronic inflammatory skin disease that severely impairs patient's life quality and represents significant therapeutic challenge due to its pathophysiology arising from skin barrier dysfunction. Topical corticosteroids, the mainstay treatment for mild to moderate AD, are usually formulated into conventional dosage forms that are impeded by low drug permeation, resulting in high doses with consequent adverse effects, and also lack properties that would strengthen the skin barrier. Herein, we aimed to develop biomimetic lamellar lyotropic liquid crystals (LLCs), offering a novel alternative to conventional AD treatment.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!